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Summary Cytotoxic microspheres have been developed for intra-arterial use in patients with liver metastases.
Following injection, the distribution of microspheres reflects the pattern of hepatic arterial blood-flow.
Vasoactive agents, such as angiotensin II, by producing vasoconstriction in normal liver, might divert arterial
blood toward tumour and thereby enhtance the delivery of drug-loaded particles. Using a double isotope
technique, the distribution of radiolablled microspheres to tumour and normal liver tissue was measured
before and after angiotensin II infusion in nine patients with multiple liver metastases. The median increase in
tumour: normal ratio following angiotensin II infusion was by a factor of 2.8 (range 0.8-11.7, P<0.05). This
novel approach to regional chemotherapy, using a combination of angiotensin II infusion and cytotoxic
microspheres, increases the exposure of tumour to cytotoxic agents and may, therefore, enhance tumour
response rates.
Sixty percent of patients dying after resection of colorectal
cancer are known to have liver metastases at the time of
death (Welch & Donaldson, 1979; Ridge & Daly, 1985). The
results of systemic chemotherapy have been disappointing;
escalation of dose or multi-drug regimes may increase the
response rate but are associated with unacceptable toxicity.
It is known that liver metastases derive their blood-supply
predominantly from the hepatic artery (Ridge et al., 1987)
and attention has therefore turned to the concept of regional
chemotherapy. In theory, the administration of cytotoxic
drugs via the hepatic artery should increase drug levels within
the tumour while minimising systemic toxicity (Kato et al.,
1981). To date, however, improved survival following bolus
intra-hepatic arterial chemotherapy has not been demon-
strated (Malik & Wrigley, 1988; Allen-Mersh, 1989). This
may be because, following bolus injection, the tumour-bear-
ing liver is exposed to high drug levels only transiently
(Goldberg et al., 1988).
One means of retaining anti-cancer agents more effectively
within the liver might be to load the active agent into
embolising particles. There have been reports of chemo-
therapeutic agents such as adriamycin and mitomycin C
being carried in biodegradable particles which act as slow-
release systems when administered via the hepatic artery
(McArdle et al., 1988; Fujimoto et al., 1985). Unfortunately,
the distribution of arterially administered particles reflects the
pattern of arterial blood-flow within the liver, and the pro-
portion of drug reaching hypovascular tumours will be low.
Previous studies in animal models have suggested that
vasoactive agents such as noradrenaline and angiotensin II
modify the pattern of arterial blood-flow by causing tem-
porary arteriolar constriction in normal blood-vessels (Bur-
ton et al., 1985). Hepatic tumour vasculature is immature,
possessing neither smooth muscle nor an adrenergic nerve
supply, and is therefore unable to respond to arterio-con-
strictors in the same way as normal vasculature (Hafstrom et
al., 1980; Mattson et al., 1977). The use of these agents might
therefore enhance the delivery of arterially administered sub-
stances to tumours.
We describe our experience with angiotensin II as a means
of targeting arterially administered particles in patients with
advanced hepatic metastases.
Patients and methods
The relative microsphere delivery to tumour and normal liver
before and after angiotensin II was measured using a double
isotope technique.
'3'Iodine ('3'I) and technetium (9Tc) labelled micro-
spheres, were prepared as described below. The particles
ranged in diameter from 20-40 lm, a size which becomes
trapped in the first capillary bed encountered when injected
intra-arterially.
Albumin microspheres were prepared by adding an aque-
ous solution of human serum albumin to a constantly stirred
oil phase to produce a water-in-oil emulsion. The micro-
spheres thus formed were stabilised with glutaraldehyde.
After mesh infiltration and differential centrifugation, micros-
pheres of the appropriate size were obtained (Lee et al., 1981;
Willmott et al., 1985). The particles were then labelled with
'"'I using the Chloramine T method (Hunter & Greenwood,
1962).
'"'I microspheres were stable in phosphate-buffered saline.
Less than 2.5% of radiolabel was found within the super-
natant after 3 months storage. The preparation was also
remarkably stable in serum, with less than 2% of the radio-
label being released after 9 days incubation.
991Tc labelled microspheres were obtained from commer-
cial sources (TDK- 5; Sorin Biomedica SpA, 13040 Saluggia
(Verchelli), Italy). This preparation is routinely used for
imaging during hepatic arterial perfusion scintigraphy; free
activity does not exceed 5%.
Tracer doses of 13'I and 9'Tc labelled albumin micro-
spheres were freshly prepared under sterile conditions before
each laparotomy. There were approximately 4 x 105 particles
per dose.
Nine patients (mean age 56 years; range 41-70 years) with
liver metastases (eight colorectal; one unknown primary)
undergoing placement of an hepatic arterial catheter for
regional chemotherapy were studied. Selective hepatic angio-
graphy was performed pre-operatively to demonstrate the
vascular anatomy. The presence of extrahepatic disease was
excluded by computed tomographic scanning and ultrasono-
graphy. The percentage hepatic replacement was assessed by
albumin colloid scan (<25% in one; 25-50% in seven and
> 50% in one patient). All those with colorectal cancer had
previously undergone resection of their primary tumour;
none had received prior treatment for their metastases. In
four patients, hepatic metastases were noted at the time of
resection, in the remainder, secondary liver involvement was
diagnosed during follow-up.
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At laparotomy, an 'hepatic artery' catheter was inserted
into the gastro-duodenal artery, so that the tip of the
catheter lay at the orifice of the gastro-duodenal artery with-
out impeding hepatic arterial blood-flow. The adequacy of
perfusion was checked using dilute methylene blue. A tracer
dose of 131I microspheres (2.5 ml) was then injected into the
catheter over 5 s and flushed with 5 ml heparinised saline
over lO s.
Angiotensin II was infused into the catheter at a rate of
1Ofig in 2 ml normal saline/min for 100 s. Immediately after
the Infusion, the tracer dose of 99'Tc microspheres in 2.5 ml
was injected over a 5 s period and flushed with 5 ml heparin-
ised saline over 1O s.
Biopsies of tumour and adjacent normal liver were obtain-
ed and weighed (mean biopsy weight 0.8 g; range 0.3-1.7 g).
The uptake of '3'I and 9'Tc in the biopsies was measured
using a gamma scintillation counter (Packard Instruments,
Auto-gamma 5000). The tissue was distributed between vials
and counted with restricted windows (120-160keV and
300-400 keV) to differentiate the activity due to the two
radio-isotopes. Standards of the 13'I and 9'9Tc were also
counted to estimate the overlap between spectra, and the
activity in each tissue sample resulting from the individual
isotopes calculated using an in-house computer program. The
relative microsphere content of the tissue samples was ex-
pressed as counts per gram of tissue and the tumour: normal
ratios of activity before and after the administration of
angiotensin II were assessed in this way.
The tumour: normal ratios before and after angiotensin II
infusion respectively were compared using the Wilcoxon
paired test.
The methodology had been approved by the local Ethical
Committee and the necessary Administration of Radioactive
Substances Advisory Committee certification obtained. In-
formed consent was obtained from all patients.
Results
The hepatic arterial infusion of angiotensin II induced a
modest rise in systemic blood-pressure (an increase in the
systolic pressure of up to 40 mmHg) which reached a peak at
the end of the 100 s infusion, then gradually declined. No
rebound hypotension was observed.
The results are summarised in Table I. Prior to the admini-
stration of angiotension II, the number of particles in the
tumour samples in all nine patients was less than that in
normal liver parenchyma. Following angiotensin II infusion,
the uptake of microspheres in tumour was greater than that
in normal liver. The median improvement in tumour: normal
ratio was 2.8 (range 0.8-11.7; P<0.05). The uptake of
microspheres more than doubled in five patients, but was
unaffected in two.
Discussion
The potential for vasoactive agents to increase drug delivery
during regional chemotherapy has been recognised for a
number of years. Early studies were performed in animal
models (Burton et al., 1985; Ackerman & Hechmer, 1977),
but more recently, there has been evidence to suggest that a
similar effect might occur in patients with intrahepatic
tumour. In 1985, Sasaki et al. (1985) described a temporary
increase in the relative arterial perfusion of human hepatic
tumours during an infusion of angiotensin II. It was suggest-
ed that a mechanism which increased the arterial perfusion to
tumours within the liver might be harnessed to increase the
tumour exposure to arterially administered chemotherapy.
In this study, we have used a radioactive microsphere
technique to assess the targeting capacity of angiotensin II.
Tracer doses of microspheres were used to minimise the
possibility of the first dose of particles significantly altering
the haemodynamics of liver blood-flow and hence the distri-
bution of the second dose of microspheres.
Despite the small number of patients studied, a significant
improvement in microsphere delivery to tumours is seen with
angiotensin II. It was interesting to note that, despite the
errors due to sampling inherent in a study of this kind, the
mean improvement in microsphere delivery to tumour after
angiotensin II was of a similar magnitude to the peak in-
crease in arterial perfusion of hepatic tumours with angio-
tenin II described by Sasaki and his colleagues.
Unfortunately, the relative increase in arterial blood flow
to hepatic tumours following angiotensin II infusion was
shown by Sasaki and his co-workers to be a relatively short-
lived effect. This mechanism would not therefore lend itself
to the targeting of substances administered by prolonged
infusion. Nevertheless, tumour targeting by angiotensin II
might be used successfully with anticancer agents given by
bolus injection, particularly if this took the form of a
particle-bound preparation.
We have previously described Adriamycin-loaded albumin
microspheres which impact in the first capillary bed following
intrahepatic-arterial injection and subsequently biodegrade,
slowly releasing the cytotoxic drug locally (McArdle et al.,
1988). Other groups have reported the use of non-biode-
gradable particles carrying mitomycin C (Kato et al., 1981)
or 'Yttrium (Mantravadi et al., 1982).
One factor which in theory would detract from the
improvement in regional selectivity seen with angiotensin II
and particle-bound cytotoxic therapy would be the presence
of arterio-venous shunting. We have previously investigated
base-line shunting and the effect of angiotensin II in patients
with advanced intraheptic metastases using radiolabelled
microspheres. We found that base-line shunting, was neg-
ligible; no significant increase was found using angiotensin II
(Goldberg et al., 1987).
Table I Uptake ofmicrospheres by tumour and normal liver before and after angiotensin II
Weight Weight Pre AII Post AII Improvement
liver tumour T:N ratio T:N ratio factor with AII:
biopsy biopsy (activity 131Iper (activity 99"Tc T:Npost AII
Patient (grams) (grams) gram tissue) per gram tissue) T:Npre AII
1 0.9 1.2 0.31 3.62 11.7
2 0.7 0.5 0.26 1.16 4.5
3 0.7 1.4 0.47 0.75 1.6
4 0.5 1.3 0.11 0.42 4.0
5 1.0 1.0 0.25 0.32 1.3
6 0.6 1.8 0.90 8.11 9.1
7* 0.5 0.6 0.60 1.68 2.8
8 0.3 0.8 0.51 0.41 0.8
9 1.0 0.9 0.11 0.10 1.0
AII = angiotensin II. T = intrahepatic tumour. N = normal liver parenchyma. = un-
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The outlook for patients with metastatic liver disease re-
mains poor; conventional therapy by intermittent bolus injec-
tion is largely ineffective. In contrast, prolonged exposure to
high drug levels may be achieved by the use of regional
chemotherapy. Cytotoxic loaded and radioactive micro-
spheres which are trapped in the capillary bed and therefore
release the cytotoxic agent locally, have been developed. The
use of a vasoactive agent such as angiotensin II to direct
these microspheres preferentially toward tumours is likely to
enhance their therapeutic effect. It remains to be seen wheth-
er the combination of cytoxic or radioactive microspheres
and targeting using a vasoactive agent such as angiotensin II
will improve survival. Unfortunately, our experience, and
that of other groups suggests that although the growth of
liver metastases may be suppressed by regional therapy, the
patients often die of extrahepatic disease. Previous studies
have shown, however, that 20-30% of patients dying of
metastases had disease confined to the liver. Clearly, better
methods of detection might allow us to identify the patients
most likely to benefit from regional therapy.
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